Glucotrack, Inc. Annual Report - How They Did This Year

I’ve updated our guide on Glucotrack, Inc. based on their 2025 annual report. If you are looking at this company, understand that they are in a "make-or-break" development phase.

1. What does the company do?

Glucotrack is a medical technology company focused on a new, implantable continuous glucose monitor for people with diabetes. They previously worked on a non-invasive ear-clip monitor but scrapped that project in 2023. They now focus entirely on this implantable technology. The device is a long-term sensor that provides real-time glucose readings, aiming to compete with market leaders by offering a "set-and-forget" user experience.

2. Financial performance

Glucotrack is currently pre-revenue and burning cash. For the year ending December 31, 2024, the company lost $14.2 million, compared to a $16.8 million loss in 2023. As of June 30, 2025, the market value of stock held by non-insiders was about $5.4 million. With $6.1 million in cash at the end of 2024, the company burns roughly $1.1 million to $1.2 million per month. This forces them to frequently raise money by selling more shares or taking on debt to stay in business.

3. Major wins and challenges

• Clinical Progress: In 2025, the company completed its first human study. The results showed the sensor’s accuracy met clinical standards. They also passed their annual ISO 13485:2016 audit, confirming their manufacturing quality meets international standards.
• Strategic Pivot: After finishing their Australian study, the company now focuses on the U.S. market. They have finalized their pre-submission package for the FDA. They plan to file for an Investigational Device Exemption in the second quarter of 2026 to start U.S. clinical trials.

4. Financial health and risks

• Dilution: To fund operations, the company sold millions of new shares. This increased the total share count by 45% last year, which reduces your ownership percentage and potential future earnings per share.
• Survival: Auditors have issued a "going concern" warning. This means the company does not have enough cash to last the next 12 months without raising more money.
• Competition: They face giants like Dexcom, Abbott, and Medtronic, who control over 90% of the market. These competitors have massive research budgets and established distribution networks that Glucotrack lacks.
• Regulatory Hurdles: The FDA approval process for this type of device is very strict. If the company fails its clinical trials or needs more data, commercialization could be delayed by up to two years. This would likely exhaust their remaining cash.

5. Future outlook

Management, which includes former executives from Dexcom and Medtronic, is prioritizing the U.S. regulatory path. Their main goal is starting a pivotal U.S. clinical trial in late 2026. Success depends on getting FDA approval and finding a way to compete against multi-billion dollar rivals.

The Bottom Line: This is a high-risk, speculative investment. You aren't buying a profitable company. You are betting that they can navigate the complex FDA process and bring their device to market before they run out of cash. Before investing, ask yourself if you are comfortable with the high probability of further share dilution and the significant risk that the company may need to raise additional capital to survive the next year.